The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $17.92

Today's change+3.73 +26.29%
Updated May 2 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $17.92

Today's change+3.73 +26.29%
Updated May 2 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc crosses above 50-day moving average

Sarepta Therapeutics Inc closed up sharply Monday, rallying (U.S.)$3.73 or 26.29% to (U.S.)$17.92 and crossing above its 50-day moving average. Over the last five days, shares have gained 19.87%, but are down 53.55% for the last year to date. Shares have outperformed the S&P 500 by 42.10% during the last year.

Key company metrics

  • Open(U.S.) $14.83
  • Previous close(U.S.) $14.19
  • High(U.S.) $18.14
  • Low(U.S.) $14.52
  • Bid / Ask(U.S.) $18.02 / (U.S.) $18.11
  • YTD % change-53.55%
  • Volume21,596,414
  • Average volume (10-day)18,244,078
  • Average volume (1-month)7,656,751
  • Average volume (3-month)3,787,655
  • 52-week range(U.S.) $8.00 to (U.S.) $41.97
  • Beta1.63
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.19
Updated May 2 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-17,560.26%

Sarepta Therapeutics Inc has a net profit margin of -17,560.26%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.62%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue1000
Total other revenue--------
Total revenue1000
Gross profit--------
Total cost of revenue--------
Total operating expense66524262
Selling / general / administrative24151323
Research & development41372939
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-64-52-42-62
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-65-52-42-62
Income after tax-65-52-42-62
Income tax, total--------
Net income-65-52-42-62
Total adjustments to net income--------
Net income before extra. items-65-52-42-62
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-65-52-42-62
Inc. avail. to common incl. extra. items-65-52-42-62
Diluted net income-65-52-42-62
Dilution adjustment--------
Diluted weighted average shares45424141
Diluted EPS excluding extraordinary itemsvalue per share-1.44-1.25-1.01-1.49
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-1.44-1.25-1.01-1.49